Equity
€7.7m ▲ 13.0%
DEVANTHINIC PHARMA has made a profit in every financial year since 2015.
DEVANTHINIC PHARMA
Lifetime
11 annual accounts with figures on one time axispeak €1.4m (2024)
€1.3m▼ 5.5%
peak €1.8m (2022)
€888,590▼ 9.6%
peak €7.7m (2025)
€7.7m▲ 13.0%
€8.7m▼ 9.7%
peak 8.4 FTE (2025)
8.4 FTE▲ 25.4%
Board1 name since 2014
1 directorANDRÉ Anne, Léa, Marie
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Staff from 6.7 FTE to 8.4 FTEEquity from €6.8m to €7.7mInvestments €44,601
Key points
from the 2025 annual accountsInvestments
€33,902 10.9 × depreciation
Green is investment, beige is depreciation. Machinery stands 303.3% higher than in 2024.
Staff
14 employees on 31-12-2025
In 2025, 8 people joined and 2 left.
Filings
11 annual accounts since 2015
Nine of the last ten came late. The 2019 accounts came latest: 87 days after the end of the period.
Group
12 companies controlled
Heads a group.
Position in the sector
€888,590
Higher net result than 95% of companies in office administrative support. Sector median €20,911 · 2,833 companies.
Holding: outside the score modelBankruptcy probability: sector outside the model
Checked score
Outside the general model
Holding: general score not applicable
The company has a registered holding activity. Financial fixed assets make up more than half of its assets. The general model for operating companies does not fit such a balance sheet, so there is no score and no financial strength.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal.
raises risk
raises risk · 2025 accounts filed 27 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
27 days late
2024
29 days late
2023
26 days late
2022
on the day
2021
26 days late
2020
30 days late
2019
87 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 32 days after the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 August (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0506893294
Appointment: ANDRÉ Anne Léa (statutory director)
Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DEVANTHINIC PHARMA Seneffe | €16.8m | €1.3m | 46.0% | 8.4 |
| DE DEURWAERDER-van PUTTEN Gistel | €26.0m | €1.2m | 88.4% | 9.2 |
| IM INVEST Asse | €19.0m | €1.0m | 72.8% | 6.5 |
| DYNERGY Beveren-Kruibeke-Zwijndrecht | €23.4m | €1.6m | 93.0% | 6.9 |
| Advanced Engineering Center Charleroi | €11.8m | €0.8m | 46.9% | 6.5 |
| STEENBERG Grimbergen | €25.4m | €1.3m | 56.2% | 6 |
| LUMET HOLDING Beveren-Kruibeke-Zwijndrecht | €16.3m | €1.2m | 12.7% | 5.9 |
These companies have the same main activity as DEVANTHINIC PHARMA: other business support services (NACE 82990). They are comparable in size and age: total assets between €12m and €26m, founded between 2008 and 2019.
Official details
Source: KBO- Status
- Active since 16-12-2014Normal situation
- Registered office
- 13 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 11 November 2026.
- Activity
- Other business support servicesNACE 82990and 1 other
- Joint committees
- 313Pharmacies and pricing offices
- 121Cleaning
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment unit
- 2.237.633.3157180 Seneffe, since 18-12-2014
- Financial year end
- 31 December
- Peppol
- Reachable since 29-12-2025
Annual accounts 2025
- ≈ €2.0mestimated
- €16.8m▲ 0.8%
- Employeeson 31-12-2025
- 14▲ 75.0%
- Filing
- Filed on 27-08-2026
Companies linked to DEVANTHINIC PHARMA
Subsidiaries and holdings
- PHARMA-LOUVE100%
- PHARMACIE ANNE ANDRE100%
- PHARMACIE BESONRIEUX CENTRE100%
- PHARMACIE DE BASCOUP100%
- PHARMACIE DE BOIS-D'HAINE100%
- PHARMACIE DE LA DRÊVE100%
- PHARMACIE DE LA GRAND RUE100%
- PHARMACIE DE LA VILLE BASSE100%
Insights on DEVANTHINIC PHARMA
DEVANTHINIC PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €34,196 in 2015 to €1.3m in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DEVANTHINIC PHARMA
- What is the company number of DEVANTHINIC PHARMA?
- The company number of DEVANTHINIC PHARMA is 0506.893.294. The VAT number is the same number with BE in front: BE 0506.893.294.
- Where is DEVANTHINIC PHARMA based?
- The registered office is at Rue des Canadiens 24, 7180 Seneffe.Company details
- What does DEVANTHINIC PHARMA do?
- According to the KBO register, the main activity is other business support services (NACE 82990).
- What is the legal form of DEVANTHINIC PHARMA?
- DEVANTHINIC PHARMA is a private limited company (BV).
- When was DEVANTHINIC PHARMA founded?
- DEVANTHINIC PHARMA was founded on 16-12-2014.
- Is DEVANTHINIC PHARMA still active?
- Yes, DEVANTHINIC PHARMA is an active enterprise in the KBO register.
- How many employees does DEVANTHINIC PHARMA have?
- DEVANTHINIC PHARMA had an average of 8.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does DEVANTHINIC PHARMA fall under?
- In its 2025 annual accounts, DEVANTHINIC PHARMA states joint committees 313 (Pharmacies and pricing offices), 121 (Cleaning) and 200 (Auxiliary committee for white-collar workers).
- What is the turnover of DEVANTHINIC PHARMA?
- The turnover in financial year 2025 is ≈ €2.0m. This figure is estimated from the gross margin of €1.3m and 40 comparable companies (NACE 82). It probably lies between €1.5m and €3.0m.
- Is DEVANTHINIC PHARMA profitable?
- In financial year 2025, DEVANTHINIC PHARMA made a profit of €888,590.
- Where can I find the annual accounts of DEVANTHINIC PHARMA?
- DEVANTHINIC PHARMA filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DEVANTHINIC PHARMA due?
- DEVANTHINIC PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.DEVANTHINIC PHARMA · 15 companies See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.